Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philogen

- PMLiVE

Boehringer moves interferon-free hep C regimen into phase III

Oral combination drug achieved viral cure rate of up to 85 per cent in phase IIb

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

- PMLiVE

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

- PMLiVE

Boehringer cancer R&D programme bears first fruit

Submits afatinib in Europe to treat lung cancer

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

EMA grants accelerated assessment to Ariad’s leukaemia drug

Could cut months off approval decision for ponatinib

Novartis day

Novartis signs cancer immunotherapy deal with Penn

R&D alliance with the University of Pennsylvania will focus on novel T-cell immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links